Aragen extends collaboration with NeoVacTo manufacture lipid products for next generation lipid nanoparticles (LNP) for RNA vaccines
September 19, 2022
Hyderabad and London: Aragen Life Sciences Private Limited (“Aragen”), a global research, development, and manufacturing servcies provider (CRO/CDMO), announced that it has entered into an agreement with a UK-based company, NeoVac, for manufacturing a lipid product that will support the development of lipid nanoparticles (LNP) for use in developing RNA vaccines for various diseases.
Aragen has been working with NeoVac since early December 2021 on process research development (PRD) for the lipid product.
NeoVac is creating revolutionary and proprietary next generation LNP to enable better RNA vaccines for various diseases. The LNPs are being developed using cutting-edge technology that makes RNA vaccines more thermostable and accessible with broader capabilities and fewer side effects.
Announcing the collaboration, Dr Ramesh Subramanian, Chief Commercial Officer, Aragen, said, “We are delighted to see the extension of our collaboration with NeoVac into manufacturing. Having been associated with the project at the development phase will enable a seamless transition to the manufacturing phase. This collaboration validates Aragen’s capabilities across discovery, development and manufacturing to support our customers develop products for the betterment of people across the globe.”
NeoVac CEO, Eran Eilat M.D. Ph.D., added, “NeoVac is working on multiple RNA vaccine projects that aim to bring the next generation of this technology to millions around the world with outstanding unique qualities. Our partnership with Aragen during the development phase has been fruitful and we are happy to extend the partnership into the manufacturing phase.”
About Aragen: Aragen is a leading research and development services outsourcing partner to the global pharmaceutical, biotech, animal health and agro-chemicals industries. It offers capability for discovery, GLP safety assessment studies and development and manufacturing of small and large molecule programs. With more than 20 years experience, the Company operates through a global network of six sites with a team of 3800+ employees and 450+ PhDs. Visit www.aragen.com for more details.
About NeoVac: NeoVac is a Lipid Nanoparticles company founded at Oxford’s Harwell Innovation Centre, developing a platform for superior delivery of mRNA vaccines and treatments. NeoVac holds an exclusive novel Lipid Nanoparticle technology. Co-founded by Prof. Dan Peer and Prof. Adrian Hill, NeoVac is developing game-changing breakthrough Lipid Nanoparticle technology with superior delivery technology and fewer side effects.